Introduction ! Celiac disease is an autoimmune disorder requir− ing a gluten−free diet (GFD) for life if acute and chronic complications are to be avoided [1] . Achieving patient adherence to a GFD is difficult in some cases, because drastic changes in eating habits are required. Serological tests have become important screen− ing tools for celiac disease in the past 20 years. However, diagnosis is still based on histological criteria [1] . The use of anti−gliadin antibodies (AGA) is problematic due to the extremely low specificity of AGA−IgG and low sensitivity of AGA−IgA. For this reason AGA are no longer im− portant in the diagnosis of celiac disease [2] , but they could be useful in patients already estab− lished as having celiac disease, to monitor their adherence to a GFD, since these antibodies are prone to reappear even after slight dietary trans− gressions [3] . In these situations, anti−endomy− sial antibodies (EMA) are less sensitive [4] . Re− garding the use of IgA anti−tissue−transglutami− nase antibodies (anti−tTG), various studies have given contradictory results. Hansson et al. found that anti−tTG are reliable indicators of even brief dietary transgressions [5] , whilst Vahedi et al. challenged their usefulness in monitoring GFD adherence [6] . Among other noninvasive tests, the intestinal permeability test (IPT) using orally administered inert sugars such as lactulose and mannitol turned out to be an unreliable screening tool in children at diagnosis of celiac disease [7] because Specific author contributions: Andreas VØcsei, MD, and Ulrike Graf wrote the manuscript. All authors contributed to study design, data collec− tion and analysis, and approved the final draft for submission. The corresponding author declares that the manuscript is submitted on behalf of all authors.
Background and study aims: The best mode of follow−up in celiac disease has not yet been es− tablished. The intention of this study was to clar− ify which noninvasive follow−up investigation ± serological tests or intestinal permeability test (IPT) ± correlates best with histology and wheth− er the interval between diagnosis and follow−up affects the accuracy of these tests. Patients and methods: Data from adult patients with celiac disease (diagnosed between Decem− ber 1989 and July 2006) followed up with biopsy, IPT, and serological tests [IgG anti−gliadin antibo− dies (AGA−IgG), AGA−IgA, and endomysial antibo− dies (EMA)] were retrieved from a computerized database. Results of noninvasive tests were com− pared with the persistence of villous atrophy on biopsy. Patients were divided into groups A, which comprised patients followed up within 2 years after diagnosis, and B, comprising patients followed up later than 2 years. Results: Forty−seven patients were evaluable. The lactulose/mannitol (L/M) ratio had a sensitiv− ity of 85 % and a specificity of 46.2 % for mucosal atrophy, whereas saccharose excretion showed a sensitivity of 60 % and a specificity of 52.6 %. The sensitivities of AGA−IgA and AGA−IgG were 15 % and 20 %, respectively, while specificity was 100 % for both. Validity of AGA was limited due to low number of positive results. EMA assay was 50 % sensitive and 77.8 % specific. In group A (n = 23) L/M ratio performed best in terms of sen− sitivity (88.9 %), whereas EMA achieved a higher specificity (71.4 %). In group B, the sensitivity of the L/M ratio decreased to 85.7 %, while the speci− ficity of EMA increased to 91.7 %. Conclusions: In this study, none of the noninva− sive tests was an accurate substitute for follow− up biopsy in detecting severe mucosal damage. of its low specificity for discriminating between healthy subjects and those with celiac disease. However, for follow−up in adults IPT recently was proven superior to AGA−IgA in detecting per− sistent mucosal alterations during a GFD [8] . Furthermore, intes− tinal permeability normalizes in the majority of individuals with celiac disease who are on a strict GFD. Gluten ingestion as meas− ured by a 3−day food record correlates with changes in the IPT [9] . Nevertheless, biopsy remains the gold standard for monitor− ing the effect of a GFD. The value of noninvasive tests for follow− up of celiac disease after gluten withdrawal can only be assessed by comparison with simultaneously conducted biopsies [10] . Therefore, the aim of this study was to investigate which nonin− vasive test best reflects the mucosal status by comparing the re− sults of serology and IPT with histology on follow−up. In addi− tion, we addressed the question: Does the performance of var− ious noninvasive tests vary with the length of the interval be− tween diagnosis and follow−up?
Patients and methods

!
Subjects
Data regarding all patients diagnosed with celiac disease at the Department of Gastroenterology, Medical University of Vienna, between December 1989 and July 2006, and followed by dietary history, clinical examination, and blood tests including celiac serology and IPT were retrieved from a computerized database. Serology and permeability testing was performed in all patients regularly on a yearly basis, whereas re−biopsies were not part of their routine follow−up. Only in the case of persistent EMA posi− tivity (> 1 year), suspected noncompliance, dietary resistance, or silent celiac disease at diagnosis, or else at their own request, did patients undergo repeat endoscopy at irregular intervals [11] . For final analysis, only patients with biopsy−proven celiac dis− ease followed by biopsy and simultaneous noninvasive tests were included. Patients were divided into two groups (A, B) according to follow− up time. Patients allocated to group A were followed for up to 2 years after diagnosis, patients from group B for longer. Sub− groups were defined in respect of normal villous architecture (groups A1 and B1) and persistent mucosal damage (groups A2 and B2) on follow−up histology.
Dietary assessment
Adherence to a GFD was assessed by a physician at follow−up. Patients were classified as either keeping a strict GFD or admit− ting dietary transgressions at least once a month.
Biopsy
Upper gastrointestinal endoscopy was performed using an Olympus gastroscope with an Endoflex KF225B (Endoflex, Voerde, Germany) and Olympus FB24K−1 Forceps (Olympus Austria, Vienna, Austria) with an open−cup diameter of 7 mm. Four biopsies were taken from the second part of the duodenum and two from the bulb, the latter having shown equal or superior diagnostic value to more distal biopsies [12] . The intestinal biopsy specimens were fixed in 4 % phosphate− buffered formalin (pH 7.4) for histological analysis. Celiac dis− ease was diagnosed according to modified ESPGHAN (European Society of Pediatric Gastroenterology, Hepatology, and Nutri− tion) criteria [13] . Morphological characteristics of the crypts and villi and the number of intraepithelial lymphocytes (IEL) were included in the report. The stages of histological changes were classified using a modified Marsh classification [14] .
Serology
EMA−IgA levels were determined by an immunofluorescence as− say using monkey esophagus sections (Biosystems, Barcelona, Spain) according to the manufacturer's instructions. Sera were tested starting with a screening dilution of 1 : 10. Results were rated as positive if an apple−green luminescent fluorescence pat− tern of the intermyofibril substance of the smooth muscle was observed. All slides were assessed by the same experienced ob− server. AGA−IgA levels were measured by enzyme−linked immunosor− bent assay (ELISA) (1989 ± 2003: Gluten IgA EIA, Pharmacia GmbH Diagnostics, Freiburg, Germany; 2003 ± 2005: Pharmacia CAP System, Uppsala, Sweden; since 2005: QUANTA Lite Gliadin IgA, Inova Diagnostics, Inc., San Diego, USA). Cut−offs were 25 U/ ml, 2.5 U/ml, and 30 U/ml, respectively for the three different as− says. AGA−IgG levels were assessed by ELISA (materials sourced as for AGA−AgA). Cut−offs were 25 U/ml, 25 U/ml, and 30 U/ml, respec− tively.
Intestinal permeability test
A sugar test solution containing 20 g saccharose, 10 g lactulose, and 5 g mannitol dissolved in 100 ml water was administered to the patients. Lactulose and mannitol concentrations in a 5−hour urine collection were measured by high−performance liquid chromatography as previously described [15] . An L/M ratio above 0.03 was considered a positive test result indicating in− creased intestinal permeability. For gastroduodenal permeabil− ity, the urinary concentration of saccharose was determined by UV spectrometry (Sucrose/D−Glucose/D−Fructose UV Test Assay, Boehringer Mannheim, Mannheim, Germany) [16] . Values above 43 mg were indicative of increased gastroduodenal permeabil− ity.
Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences for Windows 15.0. The x 2 test was used for comparison of frequencies (positivity of various tests, gen− der) between groups A and B. The results of noninvasive tests were evaluated by calculating specificity, sensitivity, PPV, and NPV for the detection of villous atrophy with binomial 95 % exact confidence intervals (CI). For comparison of permeability parameters, the Mann±Whitney U test was performed. A P−value less than 0.05 was considered statistically significant. Patients were further subdivided into two groups according to the interval between diagnosis and follow−up. Three patients had two or more follow−up biopsies and were allocated to both groups. The results of the first follow−up within each follow−up period were evaluated. Group A (interval from diagnosis to follow−up £ 2 years, median 15 months, range 1 ± 24 months) consisted of 23 patients (7 men and 16 women, mean age 38.5 18.0 years, median age 40 years, age range 16 ± 74 years). Group B (interval from diagnosis to fol− low−up > 2 years, median 40 months, age range 26 ± 91 months) consisted of 27 patients (12 men and 15 women, mean age 44.52 16.1 years, median age 47 years, age range 17 ± 74 years). Fourteen group A patients (60.9 %) had normal or mildly altered mucosa (group A1); the remaining 9 exhibited persistent villous atrophy (group A2). Group B1 consisted of 13 patients (48.6 %) with Marsh stage 0 ± 2 disease while group B2 comprised 14 in− dividuals. No difference in persistence of villous atrophy was found between group A and group B (P = 0.407). A strict GFD was not adhered to by 17.4 % of group A and 34.6 % of group B (P = 0.173). Similarly, no differences of adherence to GFD were found in subgroup analysis (group A1 vs. A2 and B1 vs. B2; P = 0.624 and 0.075, respectively) (l " Table 1and 2).
Results
!
Study population
Results of noninvasive tests at diagnosis and follow−up
At diagnosis, L/M ratio, saccharose, and EMA proved to be most sensitive (91.3 %, 88 % and 84 %, respectively) for detecting muco− sal atrophy (Marsh ³ 3). On follow−up, L/M ratio and saccharose values were lower than the pre−GFD values (median 0.053 vs. 0.177, P = < 0.001; and me− dian 43 vs. 88 mg, P = 0.038, respectively). In addition, patients with normal villous architecture had a low− er L/M ratio than those with persistent villous atrophy, whereas saccharose showed no difference (l " Tables 1 and 3 ). However, there was no difference between these patients in the rate of po− sitivity for both IPT parameters. Regarding late follow−up, only EMA reliably discriminated between villous atrophy and normal villous architecture (group B1 vs. B2, P = 0.009) (l " Table 2 ).
Test characteristics of noninvasive tests on follow−up
The sensitivity of the L/M ratio decreased from 88.9 % at early to 85.7 % at late follow−up, whereas the specificity of EMA in− creased from 71.4 % to 91.7 % (l " Table 4 ). 
Influence of age on follow−up histology and permeability tests
No difference was found between older and younger patients (> 45 years, n = 26 vs. < 45 years, n = 21) with respect either to follow−up histology or to L/M ratio (P = 0.137 and 0.204, respec− tively).
Discussion
!
In this study we investigated which noninvasive test is best sui− ted to reflect mucosal status and therefore might be used as a substitute for small−bowel biopsy for follow−up of patients with celiac disease. We observed that IPT ± in particular the L/M ratio ± performed best in terms of sensitivity, especially if follow−up was early, but had low specificity. A normal L/M ratio excluded villous atrophy in 80 % of cases. EMA achieved the highest speci− ficity, exceeding even 90 % in patients with late follow−up.
Only one−sixth of the patients diagnosed in our clinic were com− pletely lost to follow−up, which is lower than numbers given in the literature [17] . Only one−fifth of the patients underwent small−bowel biopsy for assessment of the recovery of the duode− nal mucosa, especially those with suspected noncompliance, di− etary resistance, or silent celiac disease at diagnosis. Thus, the results from our study might be subject to a selection bias be− cause they particularly reflect the status of a difficult patient group. However, this selection bias, however, should not have any influence on the correlation of invasive with noninvasive test results. In addition, this patient group is particularly in need of easy follow−up procedures such as establishing reliable noninvasive methods as an alternative to intestinal biopsy. Slightly more than half of these patients showed no mucosal atrophy on follow−up biopsy. No difference in the proportion of patients with normalized mucosal architecture was found be− tween those followed up early as compared to those with late follow−up. Persistent villous atrophy in celiac disease, even in the absence of symptoms, carries a risk of subsequent severe complications [18] . For this reason a few centers recommend at least one follow−up biopsy to study the response to a GFD [18] . Wahab et al. reported histological remission in 65.0 % of patients within 2 years, in 85.3 % within 5 years, and in 89.9 % after 5 years of follow−up [10] . Our results did not show this improve− ment over the years, but were still superior to those found by Lee et al., who observed no villous atrophy in only 21 % of pa− tients with celiac disease patients who adhered to a GFD for an average of 8.5 years [19] . The tendency to deterioration on long− term follow−up in our study population might be due to the se− lection of patients with whose compliance was doubtful, as pre− viously mentioned. Furthermore, the longer the interval be− tween diagnosis and follow−up visits, the higher the expected proportion of patients not who do not adhere to a strict GFD. One−third of our patients in the long−term follow−up group ad− mitted not keeping a strict GFD ± a proportion also reported in other follow−up studies [20, 21] .
Regarding the IPT as a follow−up tool, only the L/M ratio achieved acceptable sensitivity, which slightly weakened over the years.
There is a clear relation between the extent of mucosal alteration and the results of the IPT at the diagnosis of celiac disease [22, 23] . Changes in the IPT after the introduction of a GFD have been reported, e. g., by comparison with the duration and extent of a GFD [9] or with serological tests [8] . Duerksen et al. demon− strated that the IPT normalizes after adherence to a GFD for more than 1 year and correlated well with ingestion of trace amounts of gluten [9] . Comparing the IPT with serological tests during a GFD, Vilela et al. found a lower L/M ratio in AGA−nega− tive patients but results remained above cutoff [8] . Among fol− low−up studies using intestinal biopsy as the gold standard, Uil et al. demonstrated a higher L/M ratio in villous atrophy than in normalized mucosa [24] . This finding is in accordance with our results (l " Table 3 ). However, only in the early follow−up period (< 2 years after diagnosis) a higher L/M ratio was observed in pa− tients with villous atrophy. Regarding the second parameter of the IPT, Vogelsang et al. showed a significant correlation of the urinary recovery of saccharose and the presence of lymphocytic gastritis in untreated celiac disease [16] . Furthermore, it was demonstrated that saccharose permeation occurs mainly through the gastric mucosa in celiac disease [16] . As can be ex− pected from these data, the saccharose test was not suitable for assessment of the status of the intestinal mucosa in our patients and showed low sensitivity and specificity, possibly due to rapid restoration of gastric mucosa. Our findings confirmed the lack of reliability of EMA for use in monitoring either compliance or histological response to treat− ment, as reported elsewhere [4, 25] [26] , who took a titer of ³ 1 : 5 as showing positivity, had a higher rate of false negative EMA results in their patients after 12 months on a GFD than we had with the higher cutoff of 1 : 10. This might be due to variations between the performance of dif− ferent EMA test kits in detecting low autoantibody titers, and might also be related to very early histological restaging in some patients. However, the performance of EMA testing chan− ged in our study in relation to the follow−up interval. Beyond 2 years after diagnosis, significantly more positive results were found in patients with persistent villous atrophy, possibly due to persistent dietary transgressions, and the specificity of EMA for detecting villous atrophy exceeded 90 %. However, it can take more than 2 years for EMA to disappear following com− mencement of a GFD, especially if titers were very high to begin with [27] . This might explain the single false positive EMA result in our group of patients who had their follow−up later than 2 years after diagnosis. Wauters et al. showed excellent sensitivity of AGA−IgA in 17 chil− dren after a gluten challenge, based on jejunal biopsies [3] . In contrast to these findings, AGA showed the lowest sensitivity of all noninvasive tests used in our adult patients. Its high specifici− ty may be explained by the extremely low rate of positive titers. However, the changing the AGA testing kit twice during the study period limits the validity of these findings.
Regarding newer serological tests in the assessment of mucosal recovery, Vahedi et al. demonstrated that anti−tTG are poor pre− dictors of dietary transgressions in adult celiac disease patients on a GFD [6] . Unfortunately, we were not able to correlate these antibodies with histological changes since anti−tTG results were available for only a few patients.
In conclusion, our results indicate that serology and IPT is far less sensitive and specific for follow−up of patients with celiac dis− ease than for screening purposes. The L/M ratio had an accept− able sensitivity in patients followed up within 2 years after diag− nosis, whereas EMA showed good specificity in those investiga− ted later than that. However, there is no replacement for intes− tinal biopsy for the accurate detection of persistent mucosal atrophy in celiac patients on a GFD.
